0TDD Stock Price and Chart — LSE:0TDD

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

Key facts today

On April 29, 2025, Novo Nordisk announced plans to sell its weight-loss drug Wegovy through telehealth firms to cash-paying U.S. customers, a move that has implications for its market strategy.

Novo Nordisk is progressing with coramitug, an antibody for ATTR amyloidosis with cardiomyopathy, currently in a Phase 2 trial with 99 patients. Results are expected in late 2025.

Novo Nordisk (NOVO_B) saw a decline of 3.9% in trading, which contributed to the overall decrease in European equities traded in the US as American depositary receipts.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.